Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) FCF Margin (2017 - 2025)

Historic FCF Margin for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to 373.08%.

  • Arcus Biosciences' FCF Margin fell 4251600.0% to 373.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 193.33%, marking a year-over-year decrease of 1290700.0%. This contributed to the annual value of 68.22% for FY2024, which is 2138300.0% up from last year.
  • Arcus Biosciences' FCF Margin amounted to 373.08% in Q3 2025, which was down 4251600.0% from 83.12% recorded in Q2 2025.
  • Arcus Biosciences' 5-year FCF Margin high stood at 3616.67% for Q1 2022, and its period low was 846.3% during Q2 2021.
  • For the 5-year period, Arcus Biosciences' FCF Margin averaged around 105.5%, with its median value being 244.44% (2022).
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 43560900bps in 2022, then tumbled by -40246700bps in 2023.
  • Arcus Biosciences' FCF Margin (Quarter) stood at 19.84% in 2021, then crashed by -938bps to 205.88% in 2022, then crashed by -47bps to 303.23% in 2023, then dropped by -28bps to 388.46% in 2024, then increased by 4bps to 373.08% in 2025.
  • Its last three reported values are 373.08% in Q3 2025, 83.12% for Q2 2025, and 475.0% during Q1 2025.